Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2022-05-13±³À°ÀÏÀÚ : 2022-05-13
±³À°Àå¼Ò : °æÁÖ È¹éÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ :
Á¦35Â÷ ´ëÇÑ´ç´¢º´ÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷)ÁÖÃÖ±â°ü : ´ëÇÑ´ç´¢º´ÇÐȸ
´ã´çÀÚ : ÀÌ¿¬ÁÖ
¿¬¶ôó : 02-714-9071
À̸ÞÀÏ :
diabetes@kams.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 1300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
°æ»óºÏµµ±³À°½Ã°£ : 6 ½Ã°£ 50ºÐ
¼¼ºÎ¼ö°·á : 170,000¿ø
ºñ°í ȸ¿ø ÀÇ»ç: 120,000¿ø ºñȸ¿ø ÀÇ»ç: 170,000¿ø ȸ¿ø ºñÀÇ»ç: 70,000¿ø ºñȸ¿ø ºñÀÇ»ç: 120,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 08:30~08:50 Initial combination therapy for T2DM; for whom, what is the optimal combination? ¹ÚÁ¤È¯(ÇѾçÀÇ´ë ³»°ú)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:00~09:25 Effect of SGLT2 inhibitors in heart failure with preserved ejection fraction ½ÉÁö¿µ(¿¬¼¼ÀÇ´ë ½ÉÀå³»°ú)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:25~09:50 Cardiovascular and renal outcomes with Finerenone with type 2 diabetes with CKD ȲÇö¼®(°æÈñÀÇ´ë ½ÅÀå³»°ú)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 09:50~10:15 Post-hoc analysis of AMPLITUDE-O study (CVOT study of Efpeglenatide) ¹é½ÂÀç(Çѹ̾àÇ° ½Å¾àÀӻ󰳹ߺ»ºÎ)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 10:15~10:40 Safety and efficacy of GLP-1/GIP dual agonists in patients with type 2 diabetes Á¶¿µ¹Î(¼¿ïÀÇ´ë ³»°ú)
Åä·Ð 05-13 °æÁÖ HICO Room1 10:40~11:00 Panel discussion Á¤Ã¢ÈñÀ̻󿼹ÌÇýÀ±ÁöÈñ(¿ï»êÀÇ´ë ³»°ú°æÈñÀÇ´ë ³»°ú¼øõÇâÀÇ´ë ³»°úÀü³²ÀÇ´ë ³»°ú)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 11:30~12:10 Tirzepatide: a dual GIP and GLP-1 receptor agonist in development for the treatment of type 2 diabetes, obesity and non-alcoholic steatohepatitis Juan Pablo Frias(Velocity Clinical Research USA)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 12:10~13:20 Intermittently scanned CGM: clinical evidence and practical tips Áø»ó¸¸(¼º±Õ°üÀÇ´ë ³»°ú)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room1 14:50~15:30 Sirtuin 6 as a multitasking player in immune cell differentiation and metabolic diseases ¹Úº´Çö(ÀüºÏÀÇ´ë »ýÈÇкÐÀÚ»ý¹°Çб³½Ç)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 15:50~16:20 Self-care solutions for GDM patients ¹ÚÇýÀº(°æÈñÀÇ·á¿ø °£È£°ú)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 16:20~16:50 Self-care solutions for children and adolescents with diabetes À̽ÂÈñ(°æºÏ´ëÇб³¾î¸°À̺´¿ø °£È£°ú)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 16:50~17:20 Self-care solutions for young diabetic patients ±è¼±¿µ(»ï¼º¼¿ïº´¿ø °£È£°ú)
±³À°½Ã°£ 05-13 °æÁÖ HICO Room2 17:20~17:50 Self-care solutions for elderly diabetic patients ¹Ú¼±¿µ(°è¸í´ëÇб³ µ¿»êÀÇ·á¿ø °£È£°ú)